Jill Ainslie

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

Bryan Burmeister, Michael A. Henderson, Jill Ainslie et al. · The Lancet Oncology · 2012 · 291 citations

Surgical Oncology, Radiation Therapy, Lymph-node Field Relapse +7

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Michael A. Henderson, Bryan Burmeister, Jill Ainslie et al. · The Lancet Oncology · 2015 · 219 citations

Surgical Oncology, Health Sciences, Radiation Therapy +9

High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07

Michael Poulsen, Danny Rischin, Euan Walpole et al. · Journal of Clinical Oncology · 2003 · 209 citations

The role of radiotherapy in the management of primary cutaneous neuroendocrine tumors (merkel cell or trabecular carcinoma): Experience at the peter maccallum cancer institute (Melbourne, Australia)

Juan Pacella, Michael Ashby, Jill Ainslie et al. · International Journal of Radiation Oncology*Biology*Physics · 1988 · 128 citations

Radiation Medicine, Merkel Cell, Radiation Therapy +8

Merkel Cell Carcinoma: 27-Year Experience at the Peter MacCallum Cancer Centre

Andrew Hui, Alison Stillie, Matthew Seel et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 77 citations

Tumor Biology, Surgical Oncology, Tumoral Pathology +9